09.01.06
UK’s MHRA Requires Warning Label on Black Cohosh Supplements
The Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. has issued a warning about black cohosh supplements: “MHRA is concerned about links between black cohosh (Actaea racemosa; syn: Cimicifuga racemosa) and the risk of liver disorders.” The basis for its concern is that the Commission on Human Medicines and the Herbal Medicines Advisory Committee have both “reviewed all available data and concluded that the data underlines an association between black cohosh and risk of liver disorders.” MHRA has therefore determined that warnings be required on labeling of black cohosh products and it “is working with the herbal sector to ensure the public is fully informed about this potential risk.”
The Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. has issued a warning about black cohosh supplements: “MHRA is concerned about links between black cohosh (Actaea racemosa; syn: Cimicifuga racemosa) and the risk of liver disorders.” The basis for its concern is that the Commission on Human Medicines and the Herbal Medicines Advisory Committee have both “reviewed all available data and concluded that the data underlines an association between black cohosh and risk of liver disorders.” MHRA has therefore determined that warnings be required on labeling of black cohosh products and it “is working with the herbal sector to ensure the public is fully informed about this potential risk.”